Health Catalyst price target lowered to $11 from $14 at Piper Sandler

Piper Sandler lowered the firm’s price target on Health Catalyst to $11 from $14 and keeps an Overweight rating on the shares. The narrative is positive, bookings outperformed in H1, demand is strong, and the company’s implementation infrastructure is ostensibly adequate, yet Heatlh Catalysts delivered in-line Q2 revenue and reiterated CY24 guidance, the analyst tells investors in a research note. The firm said it had a few questions coming out of the print, and some of those questions “persist.”